Lilly launches once-weekly Victoza rival Trulicity; Actavis taps new CFO; Zealand recruits new chief;

@FiercePharma: Top-read special report: The top 10 pharma companies by 2013 revenue. More | Follow @FiercePharma

@EricPFierce: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Story | Follow @EricPFierce

@CarlyHFierce: Dendreon bankruptcy weighs on cancer vaccine field. More | Follow @CarlyHFierce

> Eli Lilly ($LLY) said it rolled out its new diabetes drug Trulicity, which will compete with Novo Nordisk's blockbuster Victoza, in the U.S. Release

> Actavis ($ACT) brought in a new CFO, Maria Teresa Hilado, to replace the outgoing R. Todd Joyce; Hilado joins Actavis from PepsiCo, with a previous stint at Schering-Plough. Release

> Danish drugmaker Zealand Pharma has recruited Dako CEO Britt Meelby Jensen to take the reins, replacing current CEO David Solomon. Report

> Alexion Pharmaceuticals tapped SVP Julie O'Neill to replace its retiring co-founder Stephen Squinto as EVP and chief global operations officer. Report

> Portola Pharmacueticals, which is developing an antidote to newer blood-thinning medications, said it's on track with a pivotal study set for completion by the end of 2015. Release

Medical Device News

@FierceMedDev: China FDA's new medical device importation regulations shorten review period. More | Follow @FierceMedDev

@VarunSaxena2: Device that performs hundreds of tests with a single drop of blood wins Nokia Sensing Xchallenge. More | Follow @VarunSaxena2

> Thync rolling out wearable, noninvasive device to elevate mood with fresh infusion of cash in tow. More

> Medtronic makes concessions to European regulator in bid to close Covidien deal. News

> OrthAlign secures $15M to launch new navigation system for orthopedic surgery. Article

Biotech News

@FierceBiotech: Amgen takes another stride in frenzied race toward the PCSK9 finish line. More | Follow @FierceBiotech

@JohnCFierce: Triple shot IL-13/IL-4 -- Promising asthma trial prompts Regeneron, Sanofi to push dupilumab into PhIII. More | Follow @JohnCFierce

@DamianFierce: I had missed this excellent tick-tock of the last days of one Christopher A. Viehbacher. More | Follow @DamianFierce

> Takeda recruits GE to help discover new liver treatments. Item

> Threshold shares surge as PhIII cancer program enters FDA's fast track. News

> AbbVie vies for the hep C spotlight on the eve of its Gilead battle. More

Biotech Research News

> Small human study will test a new approach to fighting diabetes. More

> Research team points to Sestrin 3 as a potential new target in diabetes. Article

> Harvard investigators prep an animal study of CRISPR Cas tech for HIV. Story

> Swiss team at ETH spotlights potential of a new antibiotic found in nature. More

> Genentech R&D team fixes a flawed approach to Alzheimer's. Report

Pharma Manufacturing News

> Cadila API plant slapped for faulty follow-up on stinking APIs. Article

> Dr. Reddy's, Endo benefit from Ranbaxy manufacturing shortfalls. Item

> Plant power outage zaps the juice from AMRI's earnings. More

> Dendreon, done in by expensive, complex manufacturing, files for bankruptcy. Story

> Fresenius expansion plans in Russia sidelined by political turmoil. Article

And Finally... The Obama administration expects 9.9 million people to sign up for health coverage under Obamacare this year, 3 million fewer than a previous estimate. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.